Mesothelioma - Epidemiology and ManagementCurrent Respiratory Medicine Reviews (2011)
AbstractMesothelioma is an uncommon tumor. It has a latency period of 20-40 years. The most important risk factor is asbestos exposure. Prognosis of mesothelioma is generally poor with high case-fatality rate, and research to improve the outcome of this disease is on-going worldwide. Due to its rarity, management by a multidisciplinary team with experience is recommended. Carefully selected patients may benefit from tri-modality (surgery, radiotherapy and chemotherapy) treatment. The management of pleural and peritoneal mesothelioma is summarized in this review. Recent advances in chemotherapy and biologic response modifiers are promising.
- Pleural mesothelioma,
- Peritoneal mesothelioma,
- Malignant meosothelioma
Publication DateOctober, 2011
Citation InformationPatricia Tai, Edward Yu, Avi Assouline and Kurian Joseph. "Mesothelioma - Epidemiology and Management" Current Respiratory Medicine Reviews Vol. 7 Iss. 5 (2011)
Available at: http://works.bepress.com/edwardyu/80/